HOME >> MEDICINE >> NEWS
Drug combination boosts survival rate in head and neck cancers

ORLANDO, Fla.--Adding a third drug to a standard chemotherapy combination can dramatically improve the survival of patients with advanced head and neck cancer, according to a study led by researchers at Dana-Farber Cancer Institute in Boston. The findings will be presented at the American Society of Clinical Oncology's annual meeting.

Previous studies have shown that using combination chemotherapy of cisplatin and 5-fu yields a 25 to 50 percent rate of complete pathological responses (the tumor disappeared). Robert Haddad, MD, and his colleagues found that adding the drug docetaxel (Taxotere) to the cisplatin and 5-fu regimen significantly increased the complete pathological response rate to 89 percent. The data (Abstract 5511) will be presented as a poster discussion session on Saturday, May 14, at 1 p.m., Level 4, 414.

Using data obtained from treating 72 patients with locally advanced squamous cell carcinoma of the head and neck, the researchers project that the three-drug combination would result in a 95 percent two-year survival rate and a 90 percent five-year survival rate. The majority of these patients have stage IV disease.

"These results are very encouraging and in all likelihood will translate into a significantly more effective treatment for patients with advanced head and neck cancer," says Haddad. "This patient population historically has had a poor prognosis, but, given these findings, the outlook is more hopeful."

The drug combination is given for three cycles as an initial treatment, known as induction chemotherapy, to shrink tumors prior to several weeks of intense treatment with additional chemotherapy given along with radiation. This "sequential therapy" has brought about the most successful results in patients with these stubborn cancers. Cancers of the head and neck are diagnosed in more than 40,000 people in the United States each year, with about 7,200 deaths.

Based on recent results of Phas
'"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
14-May-2005


Page: 1 2

Related medicine news :

1. Phase II study shows combination improves survival of metastatic melanoma patients
2. Certain combination therapy found more effective for treating malaria in African children
3. To get blood pressure under control, combination of medicines may be best
4. Drug/intervention combinations offer benefit in severe CVD
5. Scripps research combination therapy obliterates new vessel growth in tumors and retinopathy
6. Drug combination slows progression of treatment resistant bone marrow cancer
7. Drug combination proves effective against myeloma in Phase I trial
8. Drug combination could reduce risk of severe asthma attacks
9. Transplant patients keep their new kidney longer with a CellCept-based drug combination
10. Rheumatoid arthritis patients can benefit from Enbrel in combination with methotrexate
11. New combination therapy after surgery improves survival for pancreatic cancer patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/15/2019)... ... , ... Heritage Woods of Rockford Administrator Jaclyn O’Keefe has been named Administrator ... is part of the NCAL Awards Program, which recognizes exemplary assisted living caregivers. Honorees ... year’s recipients is that they all go out of their way to ensure assisted ...
(Date:8/14/2019)... ... , ... New Hampshire-based Vera Roasting Company , makers of the only ... line of CBD-infused coffees with the release of a new higher-dosage organic Wellness ... “We are excited to expand our CBD-infused product lines to include a more potent ...
(Date:8/14/2019)... ... ... Today, consumers are taking a harder look at what goes into their bodies. ... levels. The trick is finding food and beverages that are delicious and nutritious to ... created Chase – a delicious, guilt free cocktail mixer that doesn’t compromise ...
(Date:8/12/2019)... ... August 12, 2019 , ... Injured ... to donations received through the 4th annual Lockton Warfighter Sports Charity Challenge being ... , Participating in the event again this year will be fifty ...
(Date:8/9/2019)... ... August 09, 2019 , ... ... its second opioid treatment program (OTP) in Ohio. MedMark Lebanon will provide medically-supervised ... The clinic, located at 1521 Walmart Drive, is now accepting patients. , ...
Breaking Medicine News(10 mins):
(Date:8/15/2019)... , ... August 15, 2019 , ... Men’s Health Memorial ... with health care experts and learn how to regain their strength and vitality. ... taking the first step to do something about it is not always easy,” said ...
(Date:8/15/2019)... ... 2019 , ... Inc. magazine revealed that Skysis is No. ... nation’s fastest-growing private companies. The list represents a unique look at the most ... Dell, Domino’s Pizza, Pandora, Timberland, LinkedIn, Yelp, Zillow, and many other well-known names ...
(Date:8/14/2019)... ANDOVER, Mass. (PRWEB) , ... August 14, 2019 ... ... Andover, Massachusetts, is continuing its research and development of its drug platform GVT ... Illness (GWI), ALS, and Parkinson’s disease among others. Overwhelming data from multiple animal ...
Breaking Medicine Technology:
Cached News: